Lower Incidence of HIV-1 Blips Observed During Integrase Inhibitor–Based Combination Antiretroviral Therapy

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 89; no. 5; pp. 575 - 582
• Main Authors: Dijkstra, Suzan, Hofstra, L. Marije, Mudrikova, Tania, Wensing, Annemarie M. J., Oomen, Patrick G. A., Hoepelman, Andy I. M., van Welzen, Berend J.
• Format: Journal Article
• Language: English
• Published: United States JAIDS Journal of Acquired Immune Deficiency Syndromes 15-04-2022; Lippincott Williams & Wilkins Ovid Technologies
• Subjects: Antiretroviral agents; Antiretroviral drugs; Antiretroviral therapy; Antiretroviral Therapy, Highly Active - adverse effects; Confidence intervals; Drug therapy; Evaluation; Failure; HIV; HIV Infections - complications; HIV Integrase Inhibitors - therapeutic use; HIV Seropositivity - complications; HIV-1; Human immunodeficiency virus; Humans; Incidence; Integrase; Non-nucleoside reverse transcriptase inhibitors; Protease inhibitors; Proteinase inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors - therapeutic use; RNA-directed DNA polymerase; Therapy; Viral Load; Viremia; Viremia - drug therapy
• ISSN: 1525-4135; 1944-7884
• DOI: 10.1097/QAI.0000000000002898

As the nature of viral blips remains unclear, their occurrence often leads to uncertainty. This study compares blip incidence rates during treatment with different combination antiretroviral therapy anchors.
Retrospective cohort study in a tertiary hospital.
All antiretroviral regimens between 2010 and 2020 containing 2 nucleos(-t)ide reverse transcriptase inhibitors and 1 anchor in virologically suppressed people living with HIV (PLWH) from our center were evaluated for the occurrence of blips [isolated viral loads (VLs) 50-499 copies/mL between measurements <50 copies/mL]. Factors associated with blips were identified using multivariable generalized estimating equation-based negative binomial models. The relationship between blips and either persistent low-level viremia (consecutive VLs ≥ 50 copies/mL not classified as failure) or virologic failure (consecutive VLs ≥ 200 or 1 VL ≥ 500 copies/mL) was also evaluated.
In total, 308 blips occurred during 3405 treatment courses in 1661 PLWH. Compared with a non-nucleoside reverse transcriptase inhibitor anchor, blip incidence was higher for protease inhibitors (incidence rate ratio 1.37; 95% confidence interval 1.05 to 1.78) and lower for integrase inhibitors (INSTIs) (incidence rate ratio 0.64; 95% confidence interval: 0.43 to 0.96). In addition, blips were associated with higher zenith VL, higher VL test frequency, and shorter time since antiretroviral therapy initiation. PLWH experiencing blips were more likely to demonstrate persistent low-level viremia but not virologic failure. Blips led to extra consultations and measurements.
INSTI-based regimens display a low number of blips. Although we found no correlation with virologic failure, the occurrence of blips led to an increased clinical burden. Further research is needed to elucidate the implications and underlying mechanisms of these findings.